Response Rates Rule In CGRP Inhibitor Migraine Studies
The primary endpoint in CGRP inhibitor trials is the average reduction in monthly headache days, but the scientific program committee chair for the recent American Headache Society meeting told Scrip that response rates are more important for doctors who treat migraine patients.
You may also be interested in...
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
Oral CGRP inhibitor atogepant delivers strong Phase IIb/III results in episodic migraine prevention less than a week after activist investors went public with their push for a management shakeup to reverse Allergan's falling stock price.